TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Tables)

Basis of Presentation and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Estimated Useful Life of Property Plant and Equipment

The estimated useful lives for the current and comparative periods are as follows:

	Useful Life
	(in years)
Plant and equipment	5-12
Furniture and fixtures	5-10
Computer equipment & software	3-5
Leasehold Improvements	Shorter of the remaining lease or estimated useful life

Schedule of Estimated Useful Lives for Current and Comparative Period

The estimated useful lives for the current and comparative periods are as follows:

	Useful Life
	(in years)
Patents and trademarks	12-17
Customer lists	5

Schedule of Earnings Per Share, Basic and Diluted Income/(loss)

The table below details the calculation of the basic and diluted income/(loss) per share for the three and nine months ended September 30, 2016 and 2015:

	Three months ended					Nine months ended
	September 30,					September 30,
	2016		2015			2016			2015
Numerator
Net Income/(Loss)	$	310,155	$	(2,326,893	)	$	(2,207,707	)	$	(5,734,921	)

Denominator
Weighted Average Basic Common Shares Outstanding		5,434,212		5,144,837			5,428,859			5,138,573
Add the Dilutive Effect of Stock Options		56,000		-			-			-
Unvested Restricted Shares		18,333		-			-			-
Weighted Average Basic and Diluted Common Shares Outstanding		5,508,545		5,144,837			5,428,859			5,138,573

Net Income/(Loss) per Share
Basic	$	0.06	$	(0.45	)	$	(0.41	)	$	(1.12	)
Diluted	$	0.06	$	(0.45	)	$	(0.41	)	$	(1.12	)